Skip to main content
SpringerLink
Log in

Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) – A new therapeutic option?

  • Perspective
  • Published:
Wiener klinische Wochenschrift Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, Woodworth TG, Brennan DC (2003) Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 3: 590–8

    Article  PubMed  Google Scholar 

  • Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD, Stegall MD (2005) New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 67: 2415–21

    Article  PubMed  Google Scholar 

  • Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T (2006) The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 69: 588–95

    Article  CAS  PubMed  Google Scholar 

  • Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B (2009) Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32: 193–203

    Article  CAS  PubMed  Google Scholar 

  • Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106–18

    Article  PubMed  Google Scholar 

  • Bajaj M, Baig R, Suraamornkul S, Hardies LJ, Coletta DK, Cline GW, Monroy A, Koul S, Sriwijitkamol A, Musi N, Shulman GI, Defronzo RA: Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab

  • Furnsinn C, Waldhausl W (2002) Thiazolidinediones: metabolic actions in vitro. Diabetologia 45: 1211–23

    Article  CAS  PubMed  Google Scholar 

  • Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427–43

    Article  CAS  PubMed  Google Scholar 

  • Singh S, Loke YK, Furberg CD (2007) Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30: 2148–53

    Article  CAS  PubMed  Google Scholar 

  • Petrica L, Petrica M, Vlad A, Dragos Jianu C, Gluhovschi G, Ianculescu C, Dumitrascu V, Giju S, Gluhovschi C, Bob F, Ursoniu S, Gadalean F, Velciov S, Bozdog G, Marian R (2009) Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. Wien Klin Wochenschr 121: 765–75

    Article  CAS  PubMed  Google Scholar 

  • Dormandy JA, Charbonnel B, Eckland DJ, et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279–89

    Article  CAS  PubMed  Google Scholar 

  • Schneider CA, Ferrannini E, Defronzo R, Schernthaner G, Yates J, Erdmann E (2008) Effect of pioglitazone on cardiovascular outcome in diabetes and chronic kidney disease. J Am Soc Nephrol 19: 182–7

    Article  CAS  PubMed  Google Scholar 

  • Sipahi I, Tuzcu EM, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B, Balog C, Shishehbor M, Magyar WA, Crowe TD, Kapadia S, Nissen SE (2007) Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. Ann Intern Med 147: 10–8

    PubMed  Google Scholar 

  • Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ (2009) Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 373: 2125–35

    Article  CAS  PubMed  Google Scholar 

  • Dormuth CR, Carney G, Carleton B, Bassett K, Wright JM (2009) Thiazolidinediones and fractures in men and women. Arch Intern Med 169: 1395–402

    Article  CAS  PubMed  Google Scholar 

  • Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK: Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 95: 592–600

  • Perico N, Remuzzi G (2007) Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney Int 72: 1419–21

    Article  CAS  PubMed  Google Scholar 

  • Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N (2008) Pioglitazone enhances the antihypertensive and renoprotective effects of candesartan in Zucker obese rats fed a high-protein diet. Hypertens Res 31: 745–55

    Article  CAS  PubMed  Google Scholar 

  • Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, Kretzler M, Feldman EL, Pennathur S, Brosius FC 3rd (2008) Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 295: F1071–81

    Article  CAS  PubMed  Google Scholar 

  • Ohtomo S, Izuhara Y, Takizawa S, Yamada N, Kakuta T, van Ypersele de Strihou C, Miyata T (2007) Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 72: 1512–9

    Article  CAS  PubMed  Google Scholar 

  • Raphael KL, Strait KA, Stricklett PK, Baird BC, Piontek K, Germino GG, Kohan DE (2009) Effect of pioglitazone on survival and renal function in a mouse model of polycystic kidney disease. Am J Nephrol 30: 468–73

    Article  CAS  PubMed  Google Scholar 

  • Kim JW, Yang JH, Park HS, Sun C, Lee SH, Cho JH, Yang CW, Yoon KH (2009) Rosiglitazone protects the pancreatic beta-cell death induced by cyclosporine A. Biochem Biophys Res Commun 390: 763–8

    Article  CAS  PubMed  Google Scholar 

  • da Silva CA, de Braganca AC, Shimizu MH, Sanches TR, Fortes MA, Giorgi RR, Andrade L, Seguro AC (2009) Rosiglitazone prevents sirolimus-induced hypomagnesemia, hypokalemia, and downregulation of NKCC2 protein expression. Am J Physiol Renal Physiol 297: F916–22

    Article  PubMed  Google Scholar 

  • Johnston O, Rose CL, Webster AC, Gill JS (2008) Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 19: 1411–8

    Article  PubMed  Google Scholar 

  • Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN: Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. Am J Kidney Dis

  • Kim MK, Ko SH, Baek KH, Ahn YB, Yoon KH, Kang MI, Lee KW, Song KH (2009) Long-term effects of rosiglitazone on the progressive decline in renal function in patients with type 2 diabetes. Korean J Intern Med 24: 227–32

    Article  CAS  PubMed  Google Scholar 

  • Trivedi H, Lu N, Andresen BT, Whaley-Connell A (2009) Slower decline of renal function after initiation of rosiglitazone in diabetics – a pilot study. Clin Nephrol 72: 181–5

    CAS  PubMed  Google Scholar 

  • Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S (2008) Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31: 1007–14

    Article  CAS  PubMed  Google Scholar 

  • Feldman L, Shani M, Efrati S, Beberashvili I, Baevsky T, Weissgarten J, Vinker S: Association between rosiglitazone use and decline in renal function in patients with type 2 diabetes mellitus. J Nephrol

  • Ramirez SP, Albert JM, Blayney MJ, Tentori F, Goodkin DA, Wolfe RA, Young EW, Bailie GR, Pisoni RL, Port FK (2009) Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol 20: 1094–101

    Article  CAS  PubMed  Google Scholar 

  • Brunelli SM, Thadhani R, Ikizler TA, Feldman HI (2009) Thiazolidinedione use is associated with better survival in hemodialysis patients with non-insulin dependent diabetes. Kidney Int 75: 961–8

    Article  CAS  PubMed  Google Scholar 

  • Cattaneo D, Bitto A, Baldelli S, Cortinovis M, Gotti E, Perico N, Remuzzi G (2008) Pharmacokinetic/pharmacodynamic drug interaction between rosiglitazone and mycophenolate mofetil in kidney transplantation: a case report. Transplantation 85: 921–2

    Article  PubMed  Google Scholar 

  • Baldwin D Jr, Duffin KE (2004) Rosiglitazone treatment of diabetes mellitus after solid organ transplantation. Transplantation 77: 1009–14

    Article  CAS  PubMed  Google Scholar 

  • Villanueva G, Baldwin D (2005) Rosiglitazone therapy of posttransplant diabetes mellitus. Transplantation 80: 1402–5

    Article  CAS  PubMed  Google Scholar 

  • Luther P, Baldwin D Jr (2004) Pioglitazone in the management of diabetes mellitus after transplantation. Am J Transplant 4: 2135–8

    Article  CAS  PubMed  Google Scholar 

  • Voytovich MH, Simonsen C, Jenssen T, Hjelmesaeth J, Asberg A, Hartmann A (2005) Short-term treatment with rosiglitazone improves glucose tolerance, insulin sensitivity and endothelial function in renal transplant recipients. Nephrol Dial Transplant 20: 413–8

    Article  CAS  PubMed  Google Scholar 

  • Han SJ, Hur KY, Kim YS, Kang ES, Kim SI, Kim MS, Kwak JY, Kim DJ, Choi SH, Cha BS, Lee HC: Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients. Nephrol Dial Transplant 25: 976–84

Download references

Author information

Authors and Affiliations

  1. Innere Medizin III, Klinische Abteilung für Nephrologie, Medizinische Universität Wien, Vienna, Austria

    Marcus D. Säemann & Michael Krebs

Authors
  1. Marcus D. Säemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Krebs
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Marcus D. Säemann or Michael Krebs.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Säemann, M., Krebs, M. Thiazolidinediones in the treatment of patients with Post-Transplant-Hyperglycemia or new-onset diabetes mellitus after renal transplantation (NODAT) – A new therapeutic option?. Wien Klin Wochenschr 122, 198–202 (2010). https://doi.org/10.1007/s00508-010-1369-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00508-010-1369-2

Keywords

Search

Navigation